MB Research & SenzaGen – In Vitro Sensitization Testing
MB Research Labs is honored to work with SenzaGen to expand our testing portfolio and include the GARD™ test platform for in vitro sensitization testing.
Genomic Allergen Rapid Detection (GARD)
Genomic Allergen Rapid Detection – GARD™ – is an in vitro platform for safety assessment of chemicals. The first GARD application, GARDskin, is a peer-reviewed assay that is considered for ECVAM validation and prioritized by the Cosmetics Europe Skin Tolerance Task Force. GARDskin is intended to replace the use of animal experiments in safety assessment of products and product constituents from the cosmetic, chemical and pharmaceutical industry.
In short, cell-cultures with in vivo like features are used as a model for the human immune system, which reacts differentially to allergenic stimulations compared to harmless substances. Following cellular stimulation, the stimulatory agent can be classified according to its hazardous properties by evaluating a set of reporter probes, so-called genomic biomarkers.
GARD Testing Platform
The GARD platform is utilizes on gene expression analysis of a stimulated in vitro dendritic cell model that mimics the key events of the immune system in response to foreign molecular structures. Transcriptional patterns induced by various stimuli are examined using predictive genomic biomarker signatures. By tailoring different biomarker signatures to specific biological endpoints of interest, the GARD™ platform is able to predict adverse effects induced by tested substances with the help of advanced pattern recognition technologies.
GARDskin
Skin sensitization testing. In Vitro allergy test for classification of skin sensitizers with outstanding accuracy. Sufficient for stand alone hazard identification.
GARDpotency
Skin sensitization potency according to GHS/CLP. In Vitro test for CLP potency classification of skin sensitizers. Add-on to GARDskin.
GARDair
Respiratory sensitization testing. In Vitro, Human dendritic-like cell line. Genomic biomarker signature monitoring innate immune function, dendritic cell activation and Th2 polarisation.
For more information about the GARD platform and other in vitro toxicology test methods.